Taiwan · Delayed Price · Currency is TWD Oneness Biotech Statistics
Total Valuation
Oneness Biotech has a market cap or net worth of TWD 24.15 billion. The enterprise value is 19.29 billion.
| Market Cap | 24.15B |
| Enterprise Value | 19.29B |
Important Dates
The next estimated earnings date is Friday, August 7, 2026.
| Earnings Date | Aug 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Oneness Biotech has 479.21 million shares outstanding. The number of shares has increased by 0.14% in one year.
| Current Share Class | 479.21M |
| Shares Outstanding | 479.21M |
| Shares Change (YoY) | +0.14% |
| Shares Change (QoQ) | -0.08% |
| Owned by Insiders (%) | 9.33% |
| Owned by Institutions (%) | 4.99% |
| Float | 300.05M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 171.87 |
| PB Ratio | 2.37 |
| P/TBV Ratio | 2.66 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -18.67 |
| EV / Sales | 137.25 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -40.04 |
Financial Position
The company has a current ratio of 37.89, with a Debt / Equity ratio of 0.04.
| Current Ratio | 37.89 |
| Quick Ratio | 36.91 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.75 |
| Interest Coverage | -92.67 |
Financial Efficiency
Return on equity (ROE) is -9.37% and return on invested capital (ROIC) is -15.78%.
| Return on Equity (ROE) | -9.37% |
| Return on Assets (ROA) | -4.20% |
| Return on Invested Capital (ROIC) | -15.78% |
| Return on Capital Employed (ROCE) | -7.38% |
| Weighted Average Cost of Capital (WACC) | 8.49% |
| Revenue Per Employee | 3.27M |
| Profits Per Employee | -24.03M |
| Employee Count | 43 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0.91 |
Taxes
In the past 12 months, Oneness Biotech has paid 3.88 million in taxes.
| Income Tax | 3.88M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.15% in the last 52 weeks. The beta is 0.79, so Oneness Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.79 |
| 52-Week Price Change | -15.15% |
| 50-Day Moving Average | 52.43 |
| 200-Day Moving Average | 61.47 |
| Relative Strength Index (RSI) | 45.17 |
| Average Volume (20 Days) | 2,906,835 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Oneness Biotech had revenue of TWD 140.52 million and -1.03 billion in losses. Loss per share was -2.16.
| Revenue | 140.52M |
| Gross Profit | 39.65M |
| Operating Income | -804.69M |
| Pretax Income | -1.04B |
| Net Income | -1.03B |
| EBITDA | -522.12M |
| EBIT | -804.69M |
| Loss Per Share | -2.16 |
Balance Sheet
The company has 5.37 billion in cash and 361.59 million in debt, with a net cash position of 5.01 billion or 10.46 per share.
| Cash & Cash Equivalents | 5.37B |
| Total Debt | 361.59M |
| Net Cash | 5.01B |
| Net Cash Per Share | 10.46 |
| Equity (Book Value) | 10.18B |
| Book Value Per Share | 20.95 |
| Working Capital | 5.58B |
Cash Flow
In the last 12 months, operating cash flow was -455.94 million and capital expenditures -25.77 million, giving a free cash flow of -481.71 million.
| Operating Cash Flow | -455.94M |
| Capital Expenditures | -25.77M |
| Depreciation & Amortization | 282.57M |
| Net Borrowing | -45.18M |
| Free Cash Flow | -481.71M |
| FCF Per Share | -1.01 |
Margins
| Gross Margin | 28.21% |
| Operating Margin | -572.63% |
| Pretax Margin | -739.52% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Oneness Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.14% |
| Shareholder Yield | -0.14% |
| Earnings Yield | -4.28% |
| FCF Yield | -1.99% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 26, 2024. It was a forward split with a ratio of 1.049967976.
| Last Split Date | Jul 26, 2024 |
| Split Type | Forward |
| Split Ratio | 1.049967976 |
Scores
Oneness Biotech has an Altman Z-Score of 20.91 and a Piotroski F-Score of 2.
| Altman Z-Score | 20.91 |
| Piotroski F-Score | 2 |